From the Editor

Nov 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In an opinion piece in the September 8 New England Journal of Medicine, Harvard medical professor and long-time industry critic Jerry Avorn takes a whack at FDA, accusing the agency of practicing a level of science that wouldn’t pass muster anywhere else in research—science that’s only "good enough for government work.";
Sep 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
My doctor and I have two different visions of an avian influenza pandemic. She's picturing regular flu season, but worse. I'm imagining 1918. Does the conflict sound familiar?
Aug 01, 2005
Pharmaceutical Executive
With patients who suffer from poverty, lack of education, and disease, it is incredibly easy to do damage through a marketing tactic that might be acceptable for another group.
Jul 01, 2005
Pharmaceutical Executive
If congressmen gathered to work through the nuances of banning ED drugs from reimbursement under Medicare, they'd still back the ban. But the decision would be grounded in lack of faith in prescribing behavior, not disregard for a debilitating condition.
Jul 01, 2005
Pharmaceutical Executive
If congressmen gathered to work through the nuances of banning ED drugs from reimbursement under Medicare, they'd still back the ban. But the decision would be grounded in lack of faith in prescribing behavior, not disregard for a debilitating condition.
Jun 01, 2005
Pharmaceutical Executive
Part of the value of a drug comes from the supply chain that protects its integrity. There's a similar supply chain that preserves the value of drug information. And it needs help.
May 01, 2005
Pharmaceutical Executive
A new TV doctor show features the most loathsome pharmaceutical executive in recent memory. But in another important way, the show is serving pharma's best interests.
Apr 01, 2005
Pharmaceutical Executive
Could it be that someone's finally going to wipe the grin off Smiling Bob's face? As we were putting this issue to bed, the Cincinnati newspapers reported that federal agents had raided the offices of Berkeley Premium Nutraceuticals, a company best known for its "natural male enhancement" pill, Enzyte, and for its repulsive television commercials starring Bob. The US Postal Service led the operation, which also included the FBI, IRS, and FDA. They froze bank accounts, sent employees home, and combed records, attempting to determine whether Berkeley, which has accumulated more than 5,000 complaints with the Cincinnati Better Business Bureau and the Ohio attorney general's office since 2001, had committed mail fraud.
Mar 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In the drug safety debate, we're hearing plenty of potential solutions. They're smart and advance desirable goals. There's just one thing wrong with them: They don't solve the problem.
native1_300x100
lorem ipsum